Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 252-043-1 | CAS number: 34454-97-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
A repeat-dose oral toxicity study with combined reproductive/developmental screening test was conducted on C4 Alcohol. The results of the study are:
A 28 day oral study resulted in a repeat dose toxicity NOAEL of 50 mg/kg/day, a male and female reproductive NOAEL of 250 mg/kg/day, and a developmental NOAEL of 50 mg/kg/day when tested according to OECD 422.
Key value for chemical safety assessment
Additional information
The subacute oral toxicity and potential for reproductive and developmental toxicity (screening level) of T-7599 (white powder, purity >99.9%, CASRN 34454-97-2, Lot 6) was evaluated in Sprague-Dawley rats following repeated oral doses. This study was performed in compliance with OECD GLP (1998), US FDA GLP 21 CFR 58, and Japanese MHW GLP (1997). The study method was based on OECD 422 (1996) and US EPA In Vivo Reproductive and Mutagenicity Tests (1982). T-7599 was prepared in 0.5% carboxymethylcellulose (CMC) for the first 4 days of the study and then was prepared in 1.0% CMC for the remainder of the study. Rats (15/sex/dose) received repeated doses of 0 (vehicle), 10, 50, or 250 mg/kg/day via oral gavage at a dose volume of 10 mL/kg. Male rats received their respective doses once daily beginning at 14 days before cohabitation and continuing after the cohabitation period for minimum total of 28 days. Female rats received their respective doses once daily beginning at 14 days before cohabitation and continuing until Day 5 of lactation (LD 5). Within each dosage group, one male rat was assigned per one female rat during the cohabitation period (maximum of 14 days). Mating was confirmed by examining female rats for spermatozoa in vaginal smears and/or absence of copulatory plug. After 36 days of dosage, all males were euthanized. On LD 5 and 6, all surviving pups and females were euthanized, respectively. Parameters evaluated: clinical observations (at least daily), body weight (daily during dosing), food consumption (at least weekly), estrous cycling, litter sizes, pup viability, clinical and necropsy observations of pups, maternal behavior, functional observational battery (5/sex/dose), and hematology and clinical biochemistry (5/sex/dose). Gross necropsy and histological evaluation of select organs were performed on males and females. All males and females survived. Significant increases in excess salivation, perioral substance and urine-stained abdominal fur was observed in the 250 mg/kg/day treated male rats. No abnormal clinical observations were noted in female rats. Body weight gains and absolute and relative food consumption were significantly reduced in the 50 and 250 mg/kg/day-treated males. Body weight gains of the females were significantly reduced during the precohabitation period in the 250 mg/kg/day dose group, but body weights and body weight gains were not significantly affected during gestation or lactation. Terminal body weights of the female rats were reduced in the 250 mg/kg/day dose group. No gross abnormalities were observed upon necropsy. Absolute liver weights were significantly increased in 250 mg/kg/day-treated males and females. Liver weights relative to terminal body weights were significantly increased in the 50 and 250 mg/kg/day treated males. The ratio of liver weight to brain weight was significantly increased in the 250 mg/kg/day-treated males and females. Microscopic examination revealed minimal or mild enlargement (hypertrophy) of centrilobular hepatocytes in most males treated at 250 mg/kg/day and in 4/10 males treated at 50 mg/kg/day. Also in three 250 mg/kg/day-treated males, necrosis of individual enlarged hepatocytes was observed in the centrilobular areas. Minimal or mild hypertrophy of centrilobular hepatocytes was also observed in most females treated at 250 mg/kg/day. In both males and females, the hypertrophy was due to an increased amount of finely granular, dense eosinophilic cytoplasm. Microscopic examination of the thymus revealed an increased incidence and severity of atrophy of the thymic lobules in female rats treated at 250 mg/kg/day. No toxicologically relevant findings in the organ weight and histopathology of the thymus in male rats. Microscopic examination of the stomach revealed focal erosions in the pyloric glandular mucosa of 2 males in the 250 mg/kg/day group. Minimal to mild edema/inflammation of the submucosa of the nonglandular and glandular areas was observed in 2 control group males, 2 males in the 50 mg/kg/day group, and 1 male in the 250 mg/kg/day group. Moderate edema/inflammation of the submucosa of the nonglandular and glandular areas was observed in 2 males in the 250 mg/kg/day group. Thus, the edema/inflammation was observed at a slightly higher incidence and severity in the 250 mg/kg/day dose group. No microscopic changes in the gastrointestinal tract of females were noted. There were no abnormal clinical or necropsy observations in the F1 generation pups. The number of liveborn pups was significantly reduced and the number of stillborn pups was significantly increased in the 250 mg/kg dosage group. The viability index and number of pups surviving per liter on postpartum day 5 were significantly reduced in the 250 mg/kg dosage group. Pup body weight was also reduced in the 250 mg/kg dosage group on postpartum days 1 and 5. Based on the results of the study, the repeat dose toxicity No Observed Adverse Effect Level (NOAEL) for the test article is 50 mg/kg/day. The male and female reproductive NOAEL is 250 mg/kg/day and the developmental NOAEL is 50 mg/kg/day.
Justification for classification or non-classification
The test article is classified as STOT RE 2 and Repr. 2 according to CLP criteria.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.